Allarity Therapeutics, INC 8-K filings

Allarity Therapeutics has stopped its Phase 2 trial of stenoparib for advanced ovarian cancer early due to significant clinical benefits observed in patients selected using their Drug Response Predictor (DRP) companion diagnostic.

Allarity Therapeutics has successfully regained compliance with the NASDAQ minimum bid price requirement after its stock maintained a closing bid price above $1.00 for more than ten consecutive trading days.

Allarity Therapeutics has received an extension until May 14, 2024, to meet Nasdaq's minimum equity requirement of $2.5 million.

Allarity Therapeutics will implement a 1-for-20 reverse stock split effective April 9, 2024, to regain compliance with Nasdaq's minimum bid price requirement.

Allarity Therapeutics has completed a 1-for-20 reverse stock split of its common stock, effective April 9, 2024, to maintain Nasdaq listing compliance.

Allarity Therapeutics is strategically shifting its focus to accelerate the development of stenoparib for advanced recurrent ovarian cancer, based on promising Phase 2 trial data and a favorable safety profile.

Allarity Therapeutics has been granted an extension until April 24, 2024, by Nasdaq to regain compliance with listing rules regarding minimum bid price and equity requirements.

Allarity Therapeutics has entered into an agreement to sell up to $947,000 of its common stock through an at-the-market offering.

Allarity Therapeutics has finalized a $660,000 convertible note agreement with 3i, LP, to bolster its working capital and cover accounts payable.

Allarity Therapeutics announced a 50% reduction in net loss from operations and positive Phase 2 trial data for its lead drug, stenoparib, in advanced ovarian cancer.

Allarity Therapeutics has terminated the employment of its Chief Medical Officer, Marie Foegh, effective February 29, 2024.

Allarity Therapeutics has amended its senior convertible notes to clarify conversion limitations and released an updated corporate presentation.

Allarity Therapeutics has finalized a $440,000 convertible note agreement and adjusted the conversion price of its Series A Preferred Stock to $0.405 per share.

Allarity Therapeutics experienced a tumultuous period with a director's resignation citing concerns over board actions and the termination of a key licensing agreement with Novartis due to a payment breach.

Allarity Therapeutics has amended its Securities Purchase Agreement to clarify the timing of purchaser's demand registration rights for shares underlying convertible notes.

Allarity Therapeutics has entered into a securities purchase agreement, issuing a senior convertible note for $440,000 to 3i, LP, with an initial purchase price of $400,000.